Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06693843 · ClinicalTrials.gov registry record · Phase 2

A Phase 2b, Dose-range Finding Study of the Efficacy and Safety of Multiple Doses of Aleniglipron (GSBR-1290) in Participants Living With Obesity or Overweight With at Least One Weight-related Comorbidity

A Phase 2 study of Obesity, Overweight, or Chronic Weight Management, sponsored by Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics.

Active
Registry status
Phase 2
Development phase
220
Enrollment target
20
Study locations

NCT06693843: Active Phase 2 study of Obesity, Overweight, or Chronic Weight Management, sponsored by Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics.

NCT06693843 is a Phase 2 study of Obesity, Overweight, or Chronic Weight Management that is active but no longer recruiting, run by Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics. The registered enrollment target is 220 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (65% higher). The trial reports 20 study locations across 10 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06693843, a Phase 2 study of Obesity, Overweight, or Chronic Weight Management, is active but no longer recruiting, sponsored by Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics.

ACTIVE NOT RECRUITING
Registry status
Phase 2
Development phase
220 participants
Enrollment target
20
Study locations

Study Summary

This study is a randomized, double-blind, placebo-controlled, dose-range finding study of the efficacy, safety, tolerability, PK, and PD of multiple doses of aleniglipron in participants living with overweight or obesity with at least one weight-related comorbidity. Participants will be randomized to aleniglipron or placebo in a ratio of 3:1 within each Cohort receiving multiple-ascending, QD doses of aleniglipron or placebo in titration steps of 4 weeks duration for a total of 36 weeks of treatment. At the end of the study (after completing 36 weeks of treatment), participants will be offered to continue with an open-label extension (OLE) where they will receive aleniglipron for an additional 36 weeks.

Primary Outcome

Double Blind Period

Conditions Studied

Obesity, Overweight, or Chronic Weight Management

Interventions

  • DRUG Aleniglipron
  • DRUG Aleniglipron or Placebo

Study Locations (20)

California

  • ACCESS Research Site - Anaheim
  • ACCESS Research Site - Los Angeles
  • ACCESS Research Site - Montclair
  • ACCESS Research Site - Rancho Cucamonga
  • ACCESS Research Site - Sacramento
  • ACCESS Research Site - Spring Valley

Illinois

  • ACCESS Research Site - Chicago
  • ACCESS Research Site - Chicago
  • ACCESS Research Site - Evanston

Missouri

  • ACCESS Research Site - City of Saint Peters
  • ACCESS Research Site - Hazelwood
  • ACCESS Research Site - Springfield

Indiana

  • ACCESS Research Site - Muncie
  • ACCESS Research Site - Valparaiso

Arizona

  • ACCESS Research Site - Phoenix

Hawaii

  • ACCESS Research Site - Honolulu

Iowa

  • ACCESS Research Site - West Des Moines

Louisiana

  • ACCESS Research Site - Baton Rouge

Trial Details

FieldValue
Enrollment Target 220 participants
Start Date 2024-10-17
Est. Completion 2026-08
Phase Phase 2
Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics

8 total trials

What the registry record for NCT06693843 still lists

NCT06693843 is an interventional study that assigns participants to a tested intervention. The registered 220 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (65% higher).

The record links to 1 condition, with Obesity, Overweight, or Chronic Weight Management appearing as the primary indexed condition, and to 2 interventions - of which Aleniglipron is the first listed.

NCT06693843 names 20 study sites across 10 states, led by California, Illinois, Missouri.

Frequently Asked Questions

What is clinical trial NCT06693843 about?

NCT06693843 is a clinical study titled "A Phase 2b, Dose-range Finding Study of the Efficacy and Safety of Multiple Doses of Aleniglipron (GSBR-1290) in Participants Living With Obesity or Overweight With at Least One Weight-related Comorbidity". This study is a randomized, double-blind, placebo-controlled, dose-range finding study of the efficacy, safety, tolerability, PK, and PD of multiple doses of aleniglipron in participants living with overweight or obesity with at least one weight-related comorbidity. Participants will be randomized t...

What is the current status of trial NCT06693843?

This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 220 participants. The study started on 2024-10-17. Estimated completion is 2026-08.

What conditions does trial NCT06693843 study?

This clinical trial studies the following conditions: Obesity, Overweight, or Chronic Weight Management.

What interventions are being tested in trial NCT06693843?

The interventions under investigation include: Aleniglipron (DRUG), Aleniglipron or Placebo (DRUG).

Who is sponsoring clinical trial NCT06693843?

This trial is sponsored by Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics, which has 8 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06693843 being conducted?

This trial has 20 study locations across Arizona, California, Hawaii, Illinois, Indiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Obesity, Overweight, or Chronic Weight Management

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT06693843's enrollment target sits among peer trials

220 275th of 2000 higher than 1,718 of 2,000 other Phase 2 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00920972 · 220 participants · Phase 1

    Campath/Fludarabine/Melphalan Transplant Conditioning for Non-Malignant Diseases

  • NCT01851642 · 220 participants

    Lung Disease and Its Affect on the Work of White Blood Cells in the Lungs

  • NCT02582021 · 220 participants

    WISE CVD - Continuation (WISE HFpEF)

  • NCT04067830 · 220 participants · Phase 2

    Respiratory Muscle Training Before Surgery in Preventing Lung Complications in Patients With Stage I-IIIB Lung Cancer

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Related registry views

Source: ClinicalTrials.gov NCT06693843, the US trial registry maintained by the National Library of Medicine. NCT06693843 (mid enrollment · wide site footprint · active not recruiting) retrieved and formatted by PlainTrial, see methodology.